<DOC>
	<DOCNO>NCT02654990</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy three different regimen PAN ( 20 mg TIW , 20 mg BIW , 10 mg TIW ) combination s.c. BTZ Dex provide exposure , safety efficacy data identify optimal regimen PAN randomize , 3-arm parallel design . This study also assess impact administer s.c. BTZ ( combination PAN Dex ) twice weekly 4 cycle , weekly start Cycle 5 disease progression patient ≤ 75 year age . Patients &gt; 75 year age receive entire treatment period s.c. BTZ weekly ( combination PAN Dex ) disease progression . Patients treat disease progression discontinue earlier due unacceptable toxicity reason . Patients discontinue study treatment reason disease progression follow efficacy every 6 week . All patient follow survival last patient enter long-term follow-up complete 3 year survival follow-up discontinue earlier .</brief_summary>
	<brief_title>Panobinostat/Bortezomib/Dexamethasone Relapsed Relapsed-and-refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>multiple myeloma per IMWG 2014 definition require treatment relapse relapsed/refractory disease measurable disease base central protein assessment 1 3 prior line therapy prior IMiD exposure acceptable lab value prior start study treatment primary refractory myeloma refractory bortezomib concomitant anticancer therapy ( BTZ/Dex bisphosphonates prior treatment DAC inhibitor Clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month prior screen ) Unresolved diarrhea ≥ CTCAE grade 2 presence medical condition associate chronic diarrhea ( irritable bowel syndrome , inflammatory bowel disease ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>relapse relapsed/refractory</keyword>
	<keyword>LBH589</keyword>
	<keyword>panobinostat</keyword>
	<keyword>bortezomib</keyword>
	<keyword>dexamethasone</keyword>
</DOC>